A 72-year-old woman with a history of glaucoma and COPD presents with acute angle-closure glaucoma attack (intraocular pressure 58 mmHg, corneal edema, mid-dilated pupil). She is already on topical timolol and dorzolamide. Acute medical management is initiated. However, the ophthalmologist notes that pilocarpine eye drops are contraindicated in this patient. What is the most appropriate next step in management to lower intraocular pressure and prepare for definitive laser peripheral iridotomy?

Explanation

## Acute Angle-Closure Glaucoma: Management Without Cholinergic Agonists This patient has **acute angle-closure glaucoma** with contraindication to pilocarpine (a direct-acting cholinergic agonist) due to underlying COPD. ### Why Pilocarpine is Contraindicated **Key Point:** Pilocarpine causes: - **Bronchospasm** (muscarinic M3 activation in airway smooth muscle) - **Increased bronchial secretions** - **Severe respiratory compromise** in COPD patients In this patient with COPD, pilocarpine risks acute respiratory decompensation — a life-threatening trade-off for IOP reduction. ### Management Algorithm Without Pilocarpine ```mermaid flowchart TD A[Acute Angle-Closure Glaucoma]:::outcome --> B{Pilocarpine Safe?}:::decision B -->|No: COPD, Asthma| C[Maximize Aqueous Suppressants]:::action B -->|Yes| D[Pilocarpine + Aqueous Suppressants]:::action C --> E[IV Acetazolamide 500 mg]:::action C --> F[Oral/IV Osmotic Agent: Mannitol or Oral Glycerol]:::action C --> G[Topical Beta-blocker + CAI Drops]:::action E --> H[IOP Reduction Achieved]:::outcome H --> I[Laser Peripheral Iridotomy]:::action D --> J[Pilocarpine Drops 1% q15min x 1 hr]:::action J --> I ``` ### Pharmacological Strategy: Aqueous Suppression Without Miotics | Drug Class | Agent | Mechanism | Onset | Role in Crisis | | --- | --- | --- | --- | --- | | **Carbonic Anhydrase Inhibitor (Topical)** | Dorzolamide, brinzolamide | ↓ aqueous production | 30 min | Already on it; continue | | **Carbonic Anhydrase Inhibitor (Systemic)** | Acetazolamide IV 500 mg | ↓ aqueous production | 15–30 min | **First-line IV agent** | | **Osmotic Agent** | Mannitol IV 1 g/kg OR Glycerol PO 50% | ↓ vitreous volume, shrinks lens | 30–60 min | **Synergistic with acetazolamide** | | **Beta-blocker (Topical)** | Timolol | ↓ aqueous production | 30 min | Already on it | | **Alpha-2 Agonist** | Apraclonidine, brimonidine | ↓ aqueous production, ↑ uveoscleral outflow | 1 hr | Adjunctive; slower onset | | **Prostaglandin Analogue** | Latanoprost, travoprost | ↑ uveoscleral outflow | 2–4 hrs | Too slow for acute crisis | | **Direct Cholinergic Agonist** | Pilocarpine | Pupillary constriction → opens angle | 15–30 min | **CONTRAINDICATED (COPD)** | **High-Yield:** In acute angle-closure glaucoma WITHOUT pilocarpine, the combination of **IV acetazolamide + osmotic agent** can lower IOP by 40–50% in 30–60 minutes, sufficient to allow laser iridotomy. ### Why This Approach Works 1. **Acetazolamide** reduces aqueous humor production by inhibiting carbonic anhydrase in ciliary body 2. **Osmotic agent** (mannitol/glycerol) shrinks vitreous volume and pulls lens-iris diaphragm backward, opening the angle 3. **Combined effect**: IOP drops enough to allow corneal clearing and visualization for laser iridotomy 4. **Laser iridotomy** is the definitive treatment — creates communication between posterior and anterior chambers, relieving angle-closure permanently **Clinical Pearl:** Pilocarpine works by miosis (pupillary constriction), which pulls the iris away from the angle. However, osmotic agents + aqueous suppressants achieve similar IOP reduction without the muscarinic side effects. ### Why Other Options Fail - **Apraclonidine alone**: Slower onset (1 hr), insufficient for acute crisis - **Prostaglandin analogues**: Onset too slow (2–4 hrs) for acute management - **Medical management alone**: Without laser iridotomy, angle-closure will recur; laser is mandatory [cite:Harrison 21e Ch 408; KD Tripathi 8e Ch 12]